Drug Type Recombinant polypeptide |
Synonyms- |
Target |
Mechanism IGF-2R inhibitors(Insulin-like growth factor II receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Angelman Syndrome | Preclinical | US | 03 Jul 2024 |